Bazedoxifene inhibits sustained STAT3 activation and increases survival in GBM
Open Access
- 1 November 2021
- journal article
- research article
- Published by Elsevier in Translational Oncology
- Vol. 14 (11) , 101192
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (P01CA062220)
This publication has 35 references indexed in Scilit:
- STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptorProceedings of the National Academy of Sciences, 2013
- Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cellsCellular Signalling, 2013
- A restricted cell population propagates glioblastoma growth after chemotherapyNature, 2012
- Suppression of Cytokine Signaling by SOCS3: Characterization of the Mode of Inhibition and the Basis of Its SpecificityImmunity, 2012
- Interleukin-6, a Major Cytokine in the Central Nervous SystemInternational Journal of Biological Sciences, 2012
- Direct In Vivo Evidence for Tumor Propagation by Glioblastoma Cancer Stem CellsPLOS ONE, 2011
- Targeting Interleukin 6 Signaling Suppresses Glioma Stem Cell Survival and Tumor GrowthStem Cells, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005